CLINICAL TRIALS PROFILE FOR BASAGLAR
✉ Email this page to a colleague
Biosimilar Clinical Trials for BASAGLAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03819790 ↗ | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Completed | Sanofi | Phase 4 | 2018-10-02 | The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM). |
| NCT03819790 ↗ | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Completed | LMC Diabetes & Endocrinology Ltd. | Phase 4 | 2018-10-02 | The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM). |
| NCT06624943 ↗ | Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali | COMPLETED | Centre Hospitalier du Luxembourg | PHASE4 | 2022-03-14 | This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe. |
| NCT06624943 ↗ | Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali | COMPLETED | Hospital of Mali | PHASE4 | 2022-03-14 | This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe. |
| NCT06624943 ↗ | Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali | COMPLETED | Sante Diabete Mali | PHASE4 | 2022-03-14 | This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for BASAGLAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03511521 ↗ | Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia | Terminated | Northwestern University | Phase 4 | 2018-03-27 | Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and outpatient setting, steroids are used for their anti-inflammatory property to treat a variety of conditions. There is a paucity of information regarding the best way to treat steroid-induced hyperglycemia. In this study we will compare (1) the addition of NPH insulin, an intermediate-acting insulin, given at the time of steroid administration to the patient's standard basal/bolus insulin to (2) modification of the standard basal-bolus insulin regimen which will consist primarily increasing the prandial doses at lunch and supper in order to determine which regimen is superior for glycemic control. |
| NCT03555305 ↗ | A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants | Completed | Eli Lilly and Company | Phase 1 | 2018-09-26 | The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented. The study will last at least 18 days, not including screening. Screening is required within 4 weeks prior to the start of the study. |
| NCT03819790 ↗ | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Completed | Sanofi | Phase 4 | 2018-10-02 | The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM). |
| NCT03819790 ↗ | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Completed | LMC Diabetes & Endocrinology Ltd. | Phase 4 | 2018-10-02 | The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM). |
| NCT04153981 ↗ | A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India | Completed | Eli Lilly and Company | Phase 4 | 2019-12-16 | The reason for this study is to see if insulin glargine is safe in participants with type 2 diabetes mellitus (T2DM) in India. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BASAGLAR
Condition Name
Clinical Trial Locations for BASAGLAR
Trials by Country
Clinical Trial Progress for BASAGLAR
Clinical Trial Phase
Clinical Trial Sponsors for BASAGLAR
Sponsor Name
